For research use only. Not for therapeutic Use.
GSK3494245 (Cat No.:I028369) is a small molecule inhibitor developed by GlaxoSmithKline that targets the BPTF protein, which is involved in gene transcription and has been implicated in various types of cancer. By inhibiting BPTF, GSK3494245 may help to slow or halt the growth of cancer cells. It has shown promise in preclinical models for the treatment of acute myeloid leukemia (AML) and other types of cancer.
| Catalog Number | I028369 |
| CAS Number | 2080410-41-7 |
| Synonyms | GSK3494245; GSK 3494245; GSK-3494245; DDD01305143; DDD-01305143; DDD 01305143; |
| Molecular Formula | C21H23FN6O2 |
| Purity | 98% |
| Solubility | Soluble in DMSO |
| Appearance | Solid powder |
| Storage | Store at -20°C |
| IUPAC Name | N-(4-fluoro-3-(3-morpholinoimidazo[1,2-a]pyrimidin-7-yl)phenyl)pyrrolidine-1-carboxamide |
| InChI | InChI=1S/C21H23FN6O2/c22-17-4-3-15(24-21(29)27-6-1-2-7-27)13-16(17)18-5-8-28-19(14-23-20(28)25-18)26-9-11-30-12-10-26/h3-5,8,13-14H,1-2,6-7,9-12H2,(H,24,29) |
| InChIKey | SAJUCKZZYFFICP-UHFFFAOYSA-N |
| SMILES | FC1=CC=C(NC(N2CCCC2)=O)C=C1C3=NC4=NC=C(N5CCOCC5)N4C=C3 |
| Reference | 1: Wyllie S, Brand S, Thomas M, De Rycker M, Chung CW, Pena I, Bingham RP, Bueren-Calabuig JA, Cantizani J, Cebrian D, Craggs PD, Ferguson L, Goswami P, Hobrath J, Howe J, Jeacock L, Ko EJ, Korczynska J, MacLean L, Manthri S, Martinez MS, Mata-Cantero L, Moniz S, Nühs A, Osuna-Cabello M, Pinto E, Riley J, Robinson S, Rowland P, Simeons FRC, Shishikura Y, Spinks D, Stojanovski L, Thomas J, Thompson S, Viayna Gaza E, Wall RJ, Zuccotto F, Horn D, Ferguson MAJ, Fairlamb AH, Fiandor JM, Martin J, Gray DW, Miles TJ, Gilbert IH, Read KD, Marco M, Wyatt PG. Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition. Proc Natl Acad Sci U S A. 2019 May 7;116(19):9318-9323. doi: 10.1073/pnas.1820175116. Epub 2019 Apr 8. PMID: 30962368; PMCID: PMC6511062. |
